摘要
登革熱（Dengue fever）已經成為全球性傳染疾病，主要流行於熱帶與亞熱帶區域。全球每年有3.9億人感染登革熱，有9600萬人產生症狀。在台灣為法定第2類傳染病。1997年世衛組織（World Health Organization，WHO）將登革熱分類成無症狀及急性發燒、典型登革熱、登革出血熱（Dengue hemorrhagic fever，DHF）與登革休克症候群（Dengue shock syndrome，DSS）。但新的研究指出部分嚴重的登革患者與此定義不相符，於是在2009年世衛組織修訂補充1997年版本不足之處，考量有無警示徵象、共存疾病、患者所處情況而分成A、B、C三組，並藉此分類來提供醫療人員對登革患者的簡易評估，期望在有限的醫療資源下，有效率地處理與治療患者。活性減毒登革熱四價疫苗目前已有一家疫苗於部分盛行國家上市，其他仍在臨床試驗階段，目前建議使用在血清陽性者接種。在更有效疫苗問世前，採取控制病媒蚊、清潔環境、監控疫區等仍是當前可行方式。
並列摘要
Dengue fever has became a global infectious disease, and it is endemic in tropical and subtropical regions. There are about 390 million infections occur annually, of which 96 million have manifestations globally. It is the secondary notifiable infectious disease in Taiwan. In 1997, World Health Organization (WHO) classified dengue fever as asymptomatic infection and acute febrile illness, classic dengue fever, dengue hemorrhasgic fever (DHF) and dengue shock syndrome (DSS). But new studies pointed out the definition didn't correspond to the preformance of partial severe dengue patients. In 2009, WHO made revision and added the insufficient part of the definition in 1997, which makes the categories of dengue patients to group A, B, C, according to the prensence of warning signs, coexist diseases and the patient’s condition. We hope to treat and manage these patients effectively in the limited medical sources by this categories. One live, attenuated, tetravalent dengue vaccine is on the market in some endemic conutries and the others are still in the clinical trial stage. It is suggested to receive a vaccination in the serum positive patients. Before the more effective vaccine comes out, to control vector mosquito and clean environment and monitor the epidemic areas are feasible ways till now.